Imidazopyridines and imidazopyrazines as LSD1 inhibitors
申请人:Incyte Corporation
公开号:US10640503B2
公开(公告)日:2020-05-05
The present invention is directed to imidazo[1,5-a]pyridine and imidazo[1,5-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
本发明涉及式 I 的咪唑并[1,5-a]吡啶和咪唑并[1,5-a]吡嗪衍生物或其药学上可接受的盐,它们是治疗癌症等疾病的 LSD1 抑制剂。
US9695168B2
申请人:——
公开号:US9695168B2
公开(公告)日:2017-07-04
[EN] IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS<br/>[FR] IMIDAZOPYRIDINES ET IMIDAZOPYRAZINES À UTILISER EN TANT QU'INHIBITEURS DE LSD1
申请人:INCYTE CORP
公开号:WO2016007731A1
公开(公告)日:2016-01-14
The present invention is directed to imidazo[l,5-a]pyridine and imidazo[l,5-a]pyrazine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS
申请人:Incyte Corporation
公开号:US20160009712A1
公开(公告)日:2016-01-14
The present invention is directed to imidazo[1,5-a]pyridine and imidazo[1,5-a]pyrazine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.